Ligand Pharmaceuticals Inc.

519 articles about Ligand Pharmaceuticals Inc.

• Ligand Announces Amgen’s KYPROLIS® Approved by FDA as Combination Regimen with DARZALEX® and Dexamethasone in Once- and Twice-Weekly Dosing Regimens for Patients with Relapsed/Refractory Multiple Myeloma

  8/24/2020

  Ligand Announces Amgen’s KYPROLIS ® Approved by FDA as Combination Regimen with DARZALEX ® and Dexamethasone in Once- and Twice-Weekly Dosing Regimens for Patients with Relapsed/Refractory Multiple Myeloma KYPROLIS is an Amgen product that utilizes Captisol ® in its formulation Approval based on the CANDOR and EQUULEUS Studies SAN DIEGO--( BUSINESS WIRE )-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that a major Capti

• 

  Ligand Buys Pfenex in $516 Million Deal to Access Protein Production Platform

  8/11/2020

  Pfenex’ proprietary protein production platform, Pfenex Expression Technology, is used to improve existing treatments and create novel therapies.

• CStone Announces That OmniAb-derived CS1001 (Anti-PD-L1) Phase 3 Trial Met the Primary Endpoint as First-Line Treatment in Stage IV Squamous and Non-squamous Non-Small Cell Lung Cancer and Announces Plans to Submit a New Drug Application

  8/7/2020

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces CStone Pharmaceuticals (“CStone”, HKEX: 2616) recently reported that its OmniAb-derived anti-PD-L1 mAb CS1001 combined with platinum-based chemotherapy met its pre-specified primary endpoint, as assessed by the independent Data Monitoring Committee at the planned interim analysis of CS1001-302, a randomized, double-blind Phase 3 clinical trial for the first-line treatment of stage IV squamous

• Ligand Reports Second Quarter 2020 Financial Results

  8/3/2020

  Ligand Pharmaceuticals Incorporated reported financial results for the three and six months ending June 30, 2020 and provided an operating forecast and program updates.

• Ligand’s Second Quarter Financial Results to be Reported August 3rd

  7/16/2020

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provided today details of its plans to report second quarter 2020 financial results on August 3, 2020.

• Ligand Announces an Expansion of Vernalis Collaboration with Servier for Research on Novel Oncology Targets

  6/15/2020

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that Vernalis Research, a Ligand company, has expanded its oncology research collaboration with Servier, an international pharmaceutical company based in France, to jointly identify and enable new therapeutic targets. The new three-year research collaboration combines Vernalis’ strengths in structure and biophysics-based methods as par

• Ligand CEO Issues Letter to Captisol Customers

  6/1/2020

  Ligand Pharmaceuticals Incorporated announces that Chief Executive Officer John Higgins issued a letter to Ligand’s Captisol® customers.

• Ligand Announces Icagen’s Expansion of Collaboration with Roche to Develop and Commercialize Therapies for Neurological Diseases

  5/29/2020

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Icagen, a Ligand Company, announced today the expansion of Icagen’s license agreement with Roche to develop and commercialize small molecule ion channel modulators for the treatment of neurological disorders, by adding a second program to the agreement. The new pro

• Ligand Earns $3 Million Milestone Payment from Palvella Therapeutics

  5/28/2020

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has earned a $3 million milestone payment from Palvella Therapeutics as a result of Palvella raising $45 million in an oversubscribed Series C financing to leading biotechnology crossover and venture investors.

• Ligand Reports First Quarter 2020 Financial Results

  5/6/2020

  Ligand Pharmaceuticals Incorporated reported financial results for the three months ended March 31, 2020 and provided an operating forecast and program updates.

• Ligand’s First Quarter Financial Results to be Reported May 6th

  4/22/2020

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provided today details of its plans to report first quarter 2020 financial results on May 6, 2020. Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg will host the conference call. What: Ligand conference call to discuss financial results and provide general business updates  

• Ligand Provides a Corporate Update and Announces May 6th as the Date for First Quarter Earnings Call

  4/6/2020

  Ligand Provides a Corporate Update and Announces May 6 th as the Date for First Quarter Earnings

• Ligand Completes Acquisition of Icagen Core Assets, Partnered Programs and Ion Channel Technologies

  4/2/2020

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the completion of its acquisition of the core assets of Icagen’s North Carolina operations

• Ligand’s Presentation at the Barclays Global Healthcare Conference Now a Webcast Only, New Slides Available on Ligand.com

  3/10/2020

  Ligand Pharmaceuticals Incorporated announces that scheduled in-person presentation at the Barclays Global Healthcare Conference in Miami Beach was changed by conference organizers to a webcast only, as the conference has been reconfigured.

• Ligand Pharmaceuticals Management to Present at Two Investor Conferences in March

  3/2/2020

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that senior management will present at two upcoming investor conferences.

• Ligand Raises 2020 Financial Guidance Due to Higher Captisol Material Sales

  2/27/2020

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces an update to its financial outlook and raises its 2020 financial guidance.

• Ligand Agrees to Acquire Core Assets, Partnered Programs and Ion Channel Technologies from Icagen

  2/11/2020

  Ligand Pharmaceuticals Incorporated announces the signing of an agreement whereby Ligand will acquire the core assets of Icagen, Inc.’s North Carolina operations, including partnered programs, proprietary ion channel screening and assay platforms, x-ray fluorescence capabilities, custom screening technologies and novel unpartnered preclinical-stage molecules for $15 million in cash.

• Ligand Reports Fourth Quarter and Full Year 2019 Financial Results

  2/6/2020

  Conference Call and Webcast with Slides Begins at 4:30 p.m. Eastern Time Today

• Ligand's Technologies Support and Enable Potential Coronavirus Treatments

  2/3/2020

  Partner Gilead Sciences’ Captisol®-enabled remdesivir (GS-5734) highlighted in the New England Journal of Medicine for treating the first case of the 2019 novel coronavirus in the United States

• Ligand Enters into OmniAb® Platform License Agreement with Pandion Therapeutics

  1/13/2020

  OmniAb technology to be accessed by Pandion for range of discovery programs